Literature DB >> 2790773

Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study.

M Sessarego1, R Defferrari, A M Dejana, A M Rebuttato, G Fugazza, E Salvidio, F Ajmar.   

Abstract

Between 1979 and 1988, 86 patients with clinical and laboratory findings consistent with essential thrombocythemia (ET) were karyotyped at diagnosis. Four patients showed a Philadelphia chromosome and underwent myeloid blastic crisis 2.5-4.5 years later, strongly suggesting a diagnosis of chronic myeloid leukemia. A partial deletion of 13q was seen in another case evolving to leukemia a few months later. Five cases, with normal karyotypes at diagnosis, developed acute transformation after more than 5 years of chronic phase. Four of them showed unusual clonal karyotype abnormalities involving different chromosomal regions. The numerical abnormalities found were trisomy 22 in one case, and trisomy 8 and 19 in another, while structural changes included partial deletion of 5p, partial deletion of 6q, pericentric inversion of chromosome 12, and partial deletion of 20q. These abnormalities have not been previously reported in ET. This investigation confirms the absence of a specific cytogenetic marker for ET, and the infrequent transformation to acute leukemia, often with chromosomal clonal disorders.

Entities:  

Mesh:

Year:  1989        PMID: 2790773     DOI: 10.1016/0165-4608(89)90127-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.

Authors:  Aleksandra Mamorska-Dyga; Jingjing Wu; Pallavi Khattar; Faisal M H Ronny; Humayun Islam; Karen Seiter; Delong Liu
Journal:  Stem Cell Investig       Date:  2016-03-24

2.  Familial essential thrombocythemia: clinical characteristics of 11 cases in one family.

Authors:  R J Schlemper; A P van der Maas; J C Eikenboom
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

3.  Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Authors:  Despina Mavrogianni; Nora Viniou; Evi Michali; Evangelos Terpos; John Meletis; George Vaiopoulos; Marina Madzourani; Gerasimos Pangalis; Xenophon Yataganas; Dimitris Loukopoulos
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

4.  Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Authors:  Matjaz Sever; Hagop Kantarjian; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

5.  Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.

Authors:  Theodore P Braun; Julia E Maxson; Anupriya Agarwal; Jennifer Dunlap; Stephen E Spurgeon; Elie Traer
Journal:  Leuk Res Rep       Date:  2014-12-25

Review 6.  Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review.

Authors:  Wen-Wen Li; Xiu-Fang Sui; Shuang Fan; Hong Xu; Cheng-Lei Wang; Fei-Ying Wang; Xiao-Dong Mo
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 7.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

Review 8.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.